ClinicalTrials.gg
Active, not recruitingNCT05627362ELMWOODUpdated Oct 23, 2026

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

A Phase 2 interventional study of Elafibranor 80 mg and Elafibranor 120 mg in Primary Sclerosing Cholangitis, sponsored by Ipsen. Active, not recruiting at 62 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ipsen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Enrollment
18th of 57
68 · median 27
Started
2022
with 2 others
Phase 2
26 of 75
6 open now
Primary completion
2031-09
later than 18 of 21 live
Registered
61st of 75
by date
Lead sponsor
2 of 75
Ipsen

Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 18th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2022, is one of 26 in phase 2, reaches primary completion later than 18 of the 21 other live ones, and was the 61st registered.

Cholangitis, Sclerosing

150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC) during the double-blind period, an initial 96 week open-label extension (OLE) period, and an optional open-label extension long-term (OLE-LT) period beyond OLE Week 96. PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the study drug, including long-term safety during the open-label extension periods. The trial will also study the study drug's effects on blood tests and other tests related to PSC disease activity.

03

Conditions studied

  • Primary Sclerosing Cholangitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following inclusion criteria apply to entry into the double-blind period and initial open-label extension (OLE) period up to OLE Week 96, unless otherwise specified.

  • Participants with a diagnosis of Primary sclerosing cholangitis (PSC) as demonstrated by the presence of the following, and in the absence of apparent causes of secondary sclerosing cholangitis: i) Historical evidence of an elevated Alkaline phosphatase (ALP) > Upper Limit Normal () since at least 6 months prior to SV1. ii) Cholangiogram (e.g. magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC) with features compatible with large duct PSC.
  • ALP ≥1.5x ULN during screening (with variability ≤30% based on two values).
  • Total ≤2.0x ULN at Screening Visit 1(SV1)
  • Participants taking ursodeoxycholic acid (UDCA) at a total daily dose ≤23 mg/kg/day, with a minimum of 6 months of stable treatment prior to screening period and expected to remain on stable dose through the 12-week DBP. Minimum of 3 months off treatment prior to screening period if UDCA was recently discontinued.
  • For participants with Inflammatory bowel disease (IBD): i) Participants with Crohn's disease must be in remission based on the investigator's clinical assessment and should be on stable treatment prior to randomisation and during screening. ii) Participants with ulcerative colitis must be in remission or have low activity disease as per the judgement of the investigator and should be on stable treatment prior to randomisation and during screening. iii) Current treatment for IBD is permitted, if the participant has been well controlled for ≥3 months prior to the screening period and is anticipated to remain on a stable dose of drugs for IBD treatment, including biologics, , immunomodulators, or systemic . iv) Participants with IBD should have a colonoscopy performed within one year prior to the screening period showing no evidence of dysplasia or cancer.
  • Medications for management of pruritus (e.g. cholestyramine, rifampin, naltrexone or sertraline) must be on a stable dose for ≥3 months prior to the screening period.
  • use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. -A female participant is eligible to participate if she is not pregnant or breastfeeding at screening, is willing not to become pregnant during the study and is willing to follow applicable protocol requirements related to this. - Male participants are eligible to participate if they agree to follow applicable protocol requirements related to contraception.
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Inclusion Criteria for Entry into Optional Open-Label Extension Long-Term (OLE-LT) Period Beyond Week 96

For entry into the optional OLE-LT period, participants:

  • Must have completed the initial OLE period up to OLE Week 96
  • Must not have permanently discontinued the study intervention during the initial OLE period
  • Must, in the opinion of the investigator, benefit from continuing to receive study intervention The eligibility criteria assessed at Screening Visit 1 (SV1) for entry into the double-blind period are not reassessed for entry into the optional OLE-LT period.

Contraception requirements applicable during the OLE-LT period:

  • Male participants: No contraception requirements apply.
  • Female participants of : Must continue to use a highly effective contraceptive method during study intervention and for at least one month after the last dose. If using a hormonal contraceptive, an additional barrier method or a switch to a highly effective non-hormonal method is required.

Exclusion criteria

Exclusion Criteria :

  • History or presence of other concomitant chronic liver disease including: i) ImmunoglobulinG 4 (IgG4) related sclerosing cholangitis, or IgG4 ≥4x at SV1. ii) Small duct PSC. iii) Documented history of secondary sclerosing cholangitis. iv) Presence of surface antigen (HBsAg) at screening. v) virus (HCV) infection vi) Primary biliary cholangitis (PBC) or positive anti-mitochondrial antibody. vii) Alcohol-related liver disease. viii) hepatitis (AIH): Simplified Diagnostic Criteria of the IAIHG ≥6. ix) Presence of history of PSC-PBC or PSC-AIH overlap syndrome. x) Non-alcoholic steatohepatitis (NASH). SMD form protocol master data--23- INT / Version 1 Known history of alpha-1 antitrypsin deficiency
  • Presence of percutaneous drain or bile duct stent at screening or within three months prior to screening.
  • History of bacterial cholangitis within 60 days prior to the screening period, or participant on antibiotics for prophylaxis of recurrent cholangitis.
  • History or any current suspicion of cholangiocarcinoma or elevated value of carbohydrate antigen 19-9 (CA19-9) >129 U/mL at SV1.
  • Alpha-fetoprotein (AFP) >20 ng/mL with 4-phase liver computerised tomography (CT) or magnetic resonance imaging (MRI) suggesting presence of liver cancer.
  • Participants with cirrhosis who are also classified as B or C based on the Child-Pugh score. Participants with cirrhosis with Child-Pugh A score are allowed.
  • History of hepatic decompensation as described in the study protocol
  • Presence or history of hepatocellular carcinoma.
  • Medical conditions that may cause non-hepatic increases in ALP (e.g. Paget's disease).
  • Medical conditions that may diminish to \<2 years, including known cancers.
  • Participant has a positive test for (HIV) type 1 or 2 at SV1, or participant is known to have tested positive for HIV.
  • Evidence of any other unstable or untreated clinically significant immunological, endocrine, neurological, gastrointestinal, haematologic, psychiatric diseases as evaluated by the investigator; other clinically significant conditions that are not well controlled
  • Known or history of malignancy within the last 5 years, with the exception of local, successfully treated basal cell carcinoma or in-situ carcinoma of the uterine cervix.
  • Participants with previous exposure to elafibranor
  • and/or AST >5x ULN
  • Albumin \<3.0 g/dL at SV1.
  • count \<100,000/microliter.
  • (INR) >1.3 due to altered hepatic function.
  • Creatine phosphokinase (CPK) >2x ULN during screening period.
  • Estimated (eGFR) \<60 mL/min/1.73m2
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Double-Blind Period: Elafibranor 80 mg

    Participant will receive two tablets per day (one tablet of elafibranor 80 mg + 1 tablet of placebo matching the 120 mg sized tablet) over the 12 weeks in Double-blind period.

    Drug: Elafibranor 80 mg · Drug: Placebo Matched to Elafibranor 120 mg

  • Experimental
    Double-Blind Period: Elafibranor 120 mg

    Participant will receive 2 tablets per day (one tablet of elafibranor 120 mg + 1 tablet of placebo matching the 80 mg sized tablet) over the 12 weeks in Double-blind period.

    Drug: Elafibranor 120 mg · Drug: Placebo Matched to Elafibranor 80 mg

  • Placebo comparator
    Double-Blind Period: Placebo

    Participant will receive 2 placebo tablets per day (one matching the 80 mg sized tablet + one matching the 120 mg sized tablet) over the 12 weeks in Double-blind period.

    Drug: Placebo Matched to Elafibranor 80 mg

  • Experimental
    Initial Open-Label Extension (OLE) Period up to OLE Week 96: Elafibranor 120 mg

    Participant will receive one tablet per day (elafibranor 120 mg) during the initial 96-weeks Open-Label extension period.

    Drug: Elafibranor 120 mg

  • Experimental
    Open-Label Extension Long-Term (OLE-LT) Period Beyond OLE Week 96: Elafibranor 120 mg

    Participant will receive one tablet per day (elafibranor 120 mg) during the optional Open-Label Extension Long-Term period beyond OLE Week 96

    Drug: Elafibranor 120 mg

Interventions

  • Oral Tablet

    Also known as: GFT505

  • Oral Tablet

    Also known as: GFT505

  • DrugPlacebo Matched to Elafibranor 80 mg

    Oral Tablet

  • DrugPlacebo Matched to Elafibranor 120 mg

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Related TEAEs, Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AESIs are AEs that may not be serious but are of special importance to a particular drug or class of drugs.

    Time frame: Double Blind Period: Baseline up to week 12, Initial Open Label Extension (OLE) Period: Baseline up to week 100, Open-Label Extension Long-Term (OLE-LT) Period Beyond OLE Week 96: OLE-LT baseline up to OLE-LT Week 260

  2. Percentage of Participants With Clinically Significant Changes in Physical Examination Findings

    Percentage of participants with clinically significant changes in physical examination findings will be reported. The clinical significance will be decided by the investigator.

    Time frame: Double Blind Period: Baseline up to week 12, Initial OLE Period: Baseline up to week 100

  3. Percentage of Participants With Clinically Significant changes in Laboratory Parameters (blood chemistry, hematology and coagulation)

    Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will be decided by the investigator.

    Time frame: Double Blind Period: Baseline up to week 12, Initial OLE Period: Baseline up to week 100

  4. Percentage of Participants With Clinically Significant Changes in Vital Signs

    Percentage of participants with clinically significant changes in Vital Signs will be reported. The clinical significance will be decided by the investigator.

    Time frame: Double Blind Period: Baseline up to week 12, Initial OLE Period: Baseline up to week 100

  5. Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Readings

    Percentage of participants with clinically significant changes in ECG readings will be reported. The clinical significance will be decided by the investigator.

    Time frame: Double Blind Period: Baseline up to week 12, Initial OLE Period: Baseline up to week 100

Secondary outcomes

  1. Relative Change From Baseline in Alkaline Phosphatase Levels (ALP)

    Time frame: Double Blind Period: Baseline, Week 12, Initial OLE Period: Baseline, Week 52, Week 96, OLE-LT Period Beyond OLE Week 96: OLE-LT baseline up to OLE-LT Week 260

  2. Percentage of Participants With ≥40% Decrease from Baseline in ALP Levels

    Time frame: Double Blind Period: Baseline, Week 12, Initial OLE Period: Baseline, Week 52, Week 96

  3. Absolute Change from Baseline in ALP

    Time frame: Double Blind Period: Baseline, Week 12, Initial OLE Period: Baseline, Week 52, Week 96

  4. Percentage of Participants With ALP: <1.3x Upper Limit of Normal (ULN) and <1.5x ULN

    Time frame: Double Blind Period: Week 12

  5. Percentage of Participants who Normalised ALP

    Time frame: Double Blind Period: Week 12

  6. Change From Baseline in Alanine Transaminase (ALT), Aspartate Transaminase (AST), Gamma-glutamyl transferase (GGT) Levels

    Time frame: Baseline, Week 12, Initial OLE-LT Period Beyond OLE Week 96: OLE-LT baseline up to OLE-LT Week 260

  7. Change From Baseline in 5' Nucleotidase and Fractionated ALP Levels at Week 12

    Time frame: Baseline, Week 12

  8. Change From Baseline in Total bilirubin Levels

    Time frame: Baseline, Week 12, Initial OLE-LT Period Beyond OLE Week 96: OLE-LT baseline up to OLE-LT Week 260

  9. Change From Baseline in Conjugated bilirubin Levels at Week 12

    Time frame: Baseline, Week 12

  10. Change From Baseline in Albumin Levels at Week 12

    Time frame: Baseline, Week 12

  11. Change from Baseline in Enhanced Liver Fibrosis (ELF) Test Score

    Time frame: Double Blind Period: Baseline, Week 12

  12. Change From Baseline in Liver Stiffness Measurement (LSM) Values Assessed by FibroScan® at Week 12

    Time frame: Double Blind Period: Baseline, Week 12

  13. Change From Baseline in Other Non-invasive Hepatic Fibrosis Serum Markers as Measured by PAI-1, TGF-β, Marker of type V Collagen Formation (Pro-C5), and Marker of Type III Collagen Formation (Pro-C3)

    Time frame: Double Blind Period: Baseline, Week 12

  14. Change From Baseline in Fibrosis-4 (FIB-4) and AST to Platelet Ratio Index (APRI)

    Time frame: Double Blind Period: Baseline, Week 12

  15. Change From Baseline in Cytokeratin-18 (CK-18) (M65 and M30) Levels

    Time frame: Double Blind Period: Baseline, Week 12

  16. Pharmacokinetics (PK) of Elafibranor and its Metabolite GFT1007: Area Under the Concentration-time Curve Over the Dosing Interval from Time 0 to 24 hours(AUC0-24)

    AUC 0-24 will be recorded from the PK blood samples collected.

    Time frame: Pre-dose, 0.5 hour (h), 1h, between 1.5 hours and 2h, 4h, and 6h after dosing at Week 4

  17. PK of Elafibranor and its Metabolite GFT1007: Maximum (peak) Observed Plasma Drug Concentration (Cmax)

    Time frame: Pre-dose, 0.5 hour (h), 1h, between 1.5h and 2h, 4h, and 6h after dosing at Week 4

  18. PK of Elafibranor and its Metabolite GFT1007: Time to Maximum Observed Drug Concentration (Tmax)

    Tmax will be recorded from the PK blood samples collected.

    Time frame: Pre-dose, 0.5 hour (h), 1h, between 1.5h and 2h, 4h, and 6h after dosing at Week 4

  19. PK of Elafibranor and its Metabolite GFT1007: Total Body Clearance (Cl/F)

    Cl/F will be recorded from the PK blood samples collected.

    Time frame: Double Blind Period: Baseline up to Week 12

  20. PK of Elafibranor and its Metabolite GFT1007: Volume of distribution (Vz)

    Vz will be recorded from the PK blood samples collected.

    Time frame: Double Blind Period: Baseline up to Week 12

  21. Number and Percentage of Participants With Clinical Outcome Events During the OLE-LT Period

    Time frame: Initial OLE-LT Period Beyond OLE Week 96: OLE-LT baseline up to OLE-LT Week 260

07

Study locations

62 sites
08

References and documents

Publications

  • Levy C, Abouda GF, Bilir BM, Bonder A, Bowlus CL, Campos-Varela I, Cazzagon N, Chandok N, Cheent K, Cortez-Pinto H, Demir M, Dill MT, Eksteen B, Fenkel JM, Gilroy R, Ko HH, Jacobson IM, Kallis Y, Kugelmas M, Luketic V, Mangia A, Montano-Loza AJ, Mukhopadhya A, Olveira A, Patel BC, Pietrangelo A, Pradhan F, Salcedo M, Shiffman ML, Sprinzl K, Swann R, Thorburn D, Thuluvath PJ, Trivedi PJ, Turnes J, Zein CO, Gomes da Silva H, Jaitly S, Miller B, Milligan C, Tavenard A, Kowdley KV. Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial. J Hepatol. 2026 Jan;84(1):74-85. doi: 10.1016/j.jhep.2025.04.025. Epub 2025 May 10. PubMed 40350321 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Sep 2031, 104 months after the start.

Of 23 phase 2 interventional studies under Cholangitis, Sclerosing, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's planned 104 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Nov 25, 2022
StartActual
Dec 29, 2022
Primary completionEst.
Sep 23, 2031
CompletionEst.
Sep 23, 2031
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 1, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05627362
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Nov 25, 2022
Start date
Dec 29, 2022
Primary completion
Sep 23, 2031 (estimated)
Completion
Sep 23, 2031 (estimated)
Last update
Oct 23, 2026

Study contacts

Ipsen Medical, Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion